Very excited about the CEN2023 conference starting in 2 weeks! The final conference schedule and conference book are now available, along with the browsable conference program. Visit cen2023.ch for more information! 𝔾𝕚𝕦𝕤𝕚 𝕄𝕠𝕗𝕗𝕒 @time_bits IBS

Very excited that my first paper for my PhD is now online! Thanks to my supervisors Pavel Mozgunov and Thomas Jaki (he/him) 🇪🇺 for all of your help! onlinelibrary.wiley.com/doi/10.1002/si…

The full program for the Australian Trials Methodology Conference 2023 is now online. Check out some of our invited speakers DAY 1 Full details: atmc23.com/schedule Tickets still available - attend in person or online!

The 7th International Symposium on Biopharmaceutical Statistics organized by the International Society for Biopharmaceutical Statistics takes place on March 6 – 9, 2024, in Baltimore. Calls for abstracts and session proposals are open isBioStat.org #ISBS2024

Delighted to share PhD student Emily Alger's latest paper which: (i) Explores analysis of patient-reported outcomes (PROs) in dose-finding oncology trials, (ii) Uncovers methodological weaknesses, and (iii) Offers recommendations for PRO analysis tinyurl.com/ryy3m3p9

EMA has adopted revised transparency rules for the publication of information on #clinicaltrials submitted through the Clinical Trials Information System in the 🇪🇺. Read more: ema.europa.eu/en/news/revise… #CTIS #Transparency

Letter to the editor just out! We consider whether we researchers should fix or simulate the complete data in simulation studies that evaluate missing methods for handling missing data. Our view: it’s very rarely appropriate to fix the complete data. 1/ doi.org/10.1002/bimj.2…

When should factorial designs be used for late-phase randomised controlled trials? Ian R White, Alexander J Szubert, Babak Choodari-Oskooei, A Sarah Walker, Mahesh KB Parmar. Clinical Trials. journals.sagepub.com/doi/full/10.11…

👋🏼 future data champions. Interested in joining a 🤩 program for your PhD? Official announcement for the European doctoral network SHARE CTD in Nature Careers. If you have a master degree in biostatistics, clinical research or related fields, have a look: nature.com/naturecareers/…

Clinical trials' analyses? The new version of ctrdata may help: an R package for EUCTR, CTIS, ISRCTN, CTGOV (classic and current) - now without external tool dependencies, corrected issues; let me know what you think. Examples and changelog: rfhb.github.io/ctrdata/news/i…

Is the familywise error rate always appropriate in clinical trials? In this paper, we propose decision-analytic approaches and derive optimal test procedures for multiple hypotheses controlling the familywise expected loss. shorturl.at/uCDFV

FDA Draft master protocol guidance is out. Here is a blog post with some details on the content, and where I expect to hear the most discussion. I encourage everyone to make comments reflecting your experiences and knowledge. berryconsultants.com/2024/01/11/blo…

New paper out! Joint work w/ E. Glimm, T. Mielke and Martin Posch on optimal allocation in platform trials Is the square root of k allocation rule used in classical multi-arm trials still the optimal solution for platform trials? Have a look at our paper! journals.sagepub.com/doi/10.1177/09…

Optimal allocation strategies in platform trials with and without the use of non-concurrent controls - joint work with Marta Bofill Roig, Ekkehard Glimm and Tobias Mielke, now available open access journals.sagepub.com/doi/10.1177/09… EU-PEARL Project

Opening the #ADMTP2024 workshop with an insightful keynote presentation by Dominic Magirr on deconstructing the Max-Combo test using visualization techniques

Inviting experts in life sciences to apply for secondment to EU Medicines Agency on #academia engagement and #regulatoryscience #research! We're a great small team supporting academic researchers & developers and advancing regulatory standards & practices. More: careers.ema.europa.eu/job/Amsterdam-…

Benjamin Saville, Department of Biostatistics, Vanderbilt University Medical Center, discusses "Conditional Power: How Likely Is Trial Success?" with JAMA Statistical Editor Roger Lewis. ja.ma/3YsYIlW

Thank you, Stephen, it was a privilege to work with you on that topic!